CytomX Therapeutics (6C1) AI Stock Analysis

Company Guidance

CytomX guided that, as of March 31, 2026, it holds $346.7M in cash, cash equivalents and investments (up from $137.1M on Dec 31, 2025), providing runway to at least the second half of 2028 and enabling prioritized investment in Varseta‑M; Q1 revenue was $10.3M (vs $50.9M Y/Y) with operating expenses of $29.8M (R&D $19.2M, G&A $10.6M). Clinically, they completed enrollment in dose‑optimization cohorts (40 patients across 8.6 and 10 mg/kg adjusted‑IBW doses), bringing Phase I enrollment to 113 patients, and expect an overall Phase I safety/efficacy update in H2 2026 (including PFS for the optimization cohort and an initial OS look) to inform FDA interactions and select a registrational dose and pivotal study targeted to begin in H1 2027. They also guided that Varseta‑M + bevacizumab data are expected by H1 2027, a Phase I/II chemo combination study will begin in H2 2026, non‑CRC expansion cohorts are planned in H2 2026, and initial CX‑801 data are expected by year‑end 2026; prior clinical metrics cited include confirmed ORR of 20–32%, median PFS ≈7 months, and an early grade‑3 diarrhea rate of ~10% in the first 20 optimization patients (with a target to manage grade‑3 events into the ~10–20% range).